Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Johnson & Johnson (NYSE:JNJ) has just made a significant technical move, achieving a Golden Cross.
This technical pattern occurs when a stock’s short-term moving average crosses above its long-term moving average, indicating a potential shift from a bearish to a bullish trend.
Chart created using Benzinga Pro
For Johnson & Johnson, the stock’s 50-day simple moving average (SMA) of $155.36 has crossed above the 200-day SMA of $154.46, signaling strong upward momentum.
A Golden Cross is considered a bullish indicator, suggesting that Johnson & Johnson stock could be entering a period of sustained upward momentum.
The stock currently trades at $164.43, comfortably above its eight-day SMA of $162.84, 20-day SMA of $161.09 and 50-day SMA of $155.36. These signals collectively point towards strong buying pressure and a bullish trend.
Johnson & Johnson’s recent submission of a Biologics License Application (BLA) to the FDA for nipocalimab, aimed at treating generalized myasthenia gravis (gMG), adds a strong fundamental tailwind to the stock.
The company's ongoing efforts to expand its oncology pipeline, combined with strategic acquisitions like V-Wave Ltd., are set to bolster its growth prospects.
With the Golden Cross in play and a series of fundamental catalysts on the horizon, Johnson & Johnson’s stock appears poised for continued strength.
The bullish technical indicators and the company’s strategic initiatives position Johnson & Johnson as a compelling opportunity for investors looking to capitalize on its upward momentum.
Read Next:
Image: Shutterstock
Posted In: JNJ